103 related articles for article (PubMed ID: 6817773)
1. Antagonism of the central effects of 3-methylclonazepam.
Darragh A; Lambe R; Brick I; O'Boyle C
Br J Clin Pharmacol; 1982 Dec; 14(6):871-2. PubMed ID: 6817773
[No Abstract] [Full Text] [Related]
2. Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil.
Curran HV; Birch B
Psychopharmacology (Berl); 1991; 103(4):519-23. PubMed ID: 1676530
[TBL] [Abstract][Full Text] [Related]
3. Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788.
Darragh A; Lambe R; O'Boyle C; Kenny M; Brick I
Psychopharmacology (Berl); 1983; 80(2):192-5. PubMed ID: 6410450
[TBL] [Abstract][Full Text] [Related]
4. Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788.
Darragh A; Lambe R; Scully M; Brick I; O'Boyle C; Downe WW
Lancet; 1981 Jul; 2(8236):8-10. PubMed ID: 6113428
[No Abstract] [Full Text] [Related]
5. Respiratory and sedative effects of clobazam and clonazepam in volunteers.
Wildin JD; Pleuvry BJ; Mawer GE; Onon T; Millington L
Br J Clin Pharmacol; 1990 Feb; 29(2):169-77. PubMed ID: 2106335
[TBL] [Abstract][Full Text] [Related]
6. Midazolam: effects on psychomotor performance and subjective aspects of sleep and sedation in normal volunteers.
Gudgeon AC; Hindmarch I
Br J Clin Pharmacol; 1983; 16 Suppl 1(Suppl 1):121S-126S. PubMed ID: 6138064
[TBL] [Abstract][Full Text] [Related]
7. Comparison of five anxiolytic benzodiazepines on measures of psychomotor performance and sleep.
Hindmarch I; Haller J; Sherwood N; Kerr JS
Neuropsychobiology; 1990-1991; 24(2):84-9. PubMed ID: 1983701
[TBL] [Abstract][Full Text] [Related]
8. Use of computerized psychomotor testing in determining CNS effects of drugs.
Berchou R; Block RI
Percept Mot Skills; 1983 Dec; 57(3 Pt 1):691-700. PubMed ID: 6664751
[TBL] [Abstract][Full Text] [Related]
9. Oxprenolol plus ethanol causes no central nervous system depression--a comparison with lorazepam plus ethanol.
Aucamp AK; Weis OF; Müller FO; Gill CE; Malan J
S Afr Med J; 1984 Sep; 66(12):445-6. PubMed ID: 6385309
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacological studies on lorazepam.
Turner P
Curr Med Res Opin; 1973; 1(5):262-4. PubMed ID: 4773188
[No Abstract] [Full Text] [Related]
11. Psychopharmacological effects of vinpocetine in normal healthy volunteers.
Subhan Z; Hindmarch I
Eur J Clin Pharmacol; 1985; 28(5):567-71. PubMed ID: 3899677
[TBL] [Abstract][Full Text] [Related]
12. RO 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.
Darragh A; Lambe R; Kenny M; Brick I; Taaffe W; O'Boyle C
Br J Clin Pharmacol; 1982 Nov; 14(5):677-82. PubMed ID: 6814472
[TBL] [Abstract][Full Text] [Related]
13. Effects of lorazepam on memory, attention and sedation in man: antagonism by Ro 15-1788.
Preston GC; Ward CE; Broks P; Traub M; Stahl SM
Psychopharmacology (Berl); 1989; 97(2):222-7. PubMed ID: 2498931
[TBL] [Abstract][Full Text] [Related]
14. Studies on the possible central and peripheral effects in man of a cholinesterase inhibitor (pyridostigmine).
Borland RG; Brennan DH; Nicholson AN; Smith PA
Hum Toxicol; 1985 May; 4(3):293-300. PubMed ID: 4007893
[TBL] [Abstract][Full Text] [Related]
15. Reversal of benzodiazepine-induced sedation by intravenous Ro 15-1788.
Darragh A; Lambe R; Brick I; Downie WW
Lancet; 1981 Nov; 2(8254):1042. PubMed ID: 6118493
[No Abstract] [Full Text] [Related]
16. Action of the benzodiazepine antagonist Ro 15-1788 in humans after sleep withdrawal.
Emrich HM; Sonderegger P; Mai N
Neurosci Lett; 1984 Jun; 47(3):369-73. PubMed ID: 6433243
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block. A double-blind placebo-controlled investigation of efficacy and safety.
Dodgson MS; Skeie B; Emhjellen S; Wickstrøm E; Steen PA
Acta Anaesthesiol Scand; 1987 Oct; 31(7):629-33. PubMed ID: 3120485
[TBL] [Abstract][Full Text] [Related]
18. A comparison of intramuscular meptazinol (100 mg) and papaveretum (20 mg) on human performance studies in healthy male volunteers.
Richens A; Allen E; Jones D; Griffiths A; Marshall R
Postgrad Med J; 1983; 59 Suppl 1():19-24. PubMed ID: 6835888
[No Abstract] [Full Text] [Related]
19. A multidimensional concept for measuring CNS effects of beta-adrenoceptor blocking agents in human pharmacology.
Wagner W; Ott H; Herrmann WM; McDonald RJ; Berzewski B
Int J Clin Pharmacol Ther Toxicol; 1981 Jan; 19(1):23-33. PubMed ID: 6110635
[No Abstract] [Full Text] [Related]
20. Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.
Currie D; Lewis RV; McDevitt DG; Nicholson AN; Wright NA
Br J Clin Pharmacol; 1988 Aug; 26(2):121-8. PubMed ID: 2905148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
